Virios Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
VIRI Nasdaq 8731 https://www.virios.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Virios Therapeutics Inc

VIRI: Enrollment Complete in Phase 2a Long COVID Trial; Results Expected in October 2024… - Aug 13th, 2024 11:49 am
Virios Therapeutics Announces Second Quarter 2024 Financial Results - Aug 8th, 2024 1:15 pm
Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 - Aug 1st, 2024 1:41 pm
Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center - Jul 23rd, 2024 1:15 pm
Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study - May 22nd, 2024 5:30 pm
Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study - May 20th, 2024 12:53 am
Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study - May 17th, 2024 8:10 pm
Virios Therapeutics, Inc. (NASDAQ:VIRI) Q1 2024 Earnings Call Transcript - May 13th, 2024 2:49 pm
VIRI: Results for Phase 2 Long COVID Trial Expected in 2H24… - May 13th, 2024 11:40 am
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update - May 9th, 2024 11:45 am
Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024 - May 2nd, 2024 1:15 pm
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID - Mar 26th, 2024 1:15 pm
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results - Feb 29th, 2024 2:15 pm
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones - Feb 28th, 2024 2:15 pm
VIRI: Moving IMC-2 into Phase 2 Program in Long COVID - Feb 7th, 2024 11:00 am
Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID - Jan 22nd, 2024 2:00 pm
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID - Jan 2nd, 2024 12:05 pm
Virios Therapeutics, Inc. (NASDAQ:VIRI) Q3 2023 Earnings Call Transcript - Nov 14th, 2023 2:55 pm
VIRI: Provides Overview of Phase 3 Program in Fibromyalgia - Nov 13th, 2023 1:00 pm
Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update - Nov 13th, 2023 12:05 pm